www.StockMarketingInc.com: Latest News!! Sign Up Now For Our Newsletter!! AMCG "Amico Games Corp. Acquires Leading Chinese Gaming Company"

STOCK MARKETING INC PRESENTS : (OTCBB: AMCG) Amico Games Corp., (AMEX: AEN) Adeona Pharmaceuticals, Inc., (OTCBB: CBAI) Cord Blood America, Inc., (OTCBB: MDCE) Medical Care Technologies Inc., (PINKSHEETS: AGCZ) Andes Gold Corp., (OTCBB: BPAC) BioPack Environmental Solutions, Inc.

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: AMCG - Amico Games Corp.)

LATEST NEWS!!

Amico Games Corp. Acquires Leading Chinese Gaming Company

SAN FRANCISCO, CA, Jan 11, 2010 -- Amico Games Corp. (OTCBB: AMCG), an information technology company specializing in developing and operating mobile phone multiplayer networked games, has acquired a leading developer of mobile phone games in China. Amico acquired Galaxy Software Limited, headquartered in Guangzhou, China, through a share exchange transaction closed on December 31, 2009.

By acquiring Galaxy, Amico acquired Galaxy's roster of mobile games, local industry expertise, 50 well trained employees and a revenue stream of over US $1.2 million during the year ended August 31, 2009.

Mr. Peter Liu, Amico's President and CEO, stated the following upon the closing of the acquisition: "Galaxy is a real leader in the mobile phone game field in China and I'm proud of completing this acquisition and providing value for our shareholders. Galaxy's mobile phone games have been exhibiting tremendous growth during the last quarter of 2009 and we're very optimistic that the recent release of Journey to the West Online, our most advanced game to date, will continue that momentum." About Amico Games Corp.

Amico Games Corp. is a software company specializing in developing mobile phone games for the Chinese market. On December 31, 2009, Amico acquired Galaxy Software Limited, a Chinese privately owned company incorporated in November 2001. Galaxy is one of the earliest mobile phone multiplayer game developers in China, as well as one of the first Chinese companies to develop and operate Java(TM) MMRPOG (massive multiplayer role playing online games) mobile phone games. It is also the first company to provide multiplayer games over the WAP platform of China Mobile, the world's largest mobile phone provider based upon subscribers. For more information, please visit the Amico's website at: www.amicogames.com

------------------------------------------------------------------------------------------------------------------------------------------------------------

(AMEX: AEN - Adeona Pharmaceuticals, Inc.)

LATEST NEWS!!

Adeona Announces Additional $860,000 Grant for Oral Estriol Multiple Sclerosis Clinical Trial

Number of Clinical Sites Doubled to Speed Enrollment

ANN ARBOR, MI, Jan 08, 2010 -- Adeona Pharmaceuticals, Inc., (AMEX: AEN), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population, announced today that the ongoing clinical trial of its Trimesta(TM) (oral estriol) drug candidate being conducted by Dr. Rhonda Voskuhl, Director, UCLA Multiple Sclerosis Program, UCLA Dept. of Neurology has received an additional $860,440 in grant funding through the American Recovery and Reinvestment Act. The current phase II/III clinical study is a double-blind, placebo-controlled trial taking place at sixteen sites in the US and will enroll up to 150 female Multiple Sclerosis (MS) patients. Investigators will administer Trimesta along with glatimer acetate (Copaxone(R)), an FDA approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. This ongoing clinical trial previously received a $5 million grant from the National Multiple Sclerosis Society (NMSS) in partnership with the National MS Society's Southern California chapter, with support from the National Institutes of Health (NIH).

According to Dr. Voskuhl, "This additional funding has already had a very positive impact on our trial. It has greatly increased the rate of enrollment by supporting the addition of 9 more clinical sites, bringing the total up to 16 sites across the US. We were extremely pleased that our trial was deemed important enough to be supplemented with these additional funds." Previous Phase II Clinical Trial Results in Relapsing Remitting Multiple Sclerosis Trimesta (oral estriol) has previously completed an initial 22-month, single-agent, crossover Phase I/II clinical trial in the US for the treatment of MS in relapsing remitting patients, with highly encouraging results. The results showed the total volume and number of enhancing pathogenic myelin lesions (established neuroimaging measurements of disease activity in MS) decreased during the treatment period as compared to a six-month pretreatment baseline period. The median total enhancing lesion volumes decreased by 79 percent (p=0.02) and the number of lesions decreased by 82 percent (p=0.09) within the first three months of treatment with Trimesta. Following a six-month drug holiday during which the patients weren't on any drug therapies, Trimesta therapy was reinitiated during a four-month retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88 percent (p=0.008) and a decrease in the number of lesions by 48 percent (p=0.04) compared with original baseline scores (1),(2).

Improvement in Cognitive Testing Scores During the prior Phase I/II clinical trial, a 14-percent improvement in Paced Auditory Serial Addition Test ("PASAT") cognitive testing scores (p=0.04) was also observed in the MS patients at six months of therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS. The PASAT scores were expressed as a mean percent change from baseline and were significantly improved in the relapsing-remitting group.

About the Trimesta Phase II/III Study In the current phase II/III study, Trimesta is being given orally once-a-day versus placebo to 150 female relapsing-remitting MS patients in combination with a standard of care background therapy, subcutaneously injected glatimer acetate. The primary endpoint for the study will evaluate effects of the treatment combination on relapse rates at two years with a one year interim analysis using standard clinical measures of MS disability as well as secondary endpoints of magnetic resonance imaging measurements of brain lesion and effects on cognition. The study is approaching 50% enrollment with the rate of enrollment benefiting significantly from the expansion of clinical sites.

About Trimesta Trimesta is an orally active, immunomodulatory and anti-inflammatory molecule which has been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes, but which has never been introduced in North America. Estriol, the active ingredient in Trimesta, is a weak estrogenic-based molecule that is produced in the placenta by women during pregnancy. Estriol is considered to play an important role in the immunologic privilege offered to the fetus during pregnancy, and is also thought to be responsible for the spontaneous remission of Th1-mediated autoimmune diseases of women (such as multiple sclerosis and rheumatoid arthritis) during pregnancy, especially during the third trimester. Adeona has an exclusive worldwide license from UCLA to issued and pending patents invented by Dr. Voskuhl including U.S. Patent 6,936,599 covering estriol's use for MS. While currently marketed therapies for MS sell billions of dollars annually, all require frequent injections and currently is no FDA-approved oral therapy for the treatment of MS.

About Adeona Pharmaceuticals, Inc.

Adeona Pharmaceuticals, Inc. (AMEX: AEN) is a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population. Adeona believes that these conditions may contribute to the progression of debilitating degenerative diseases, including, Dry Age-Related Macular Degeneration (Dry AMD), Alzheimer's disease (AD) and mild cognitive impairment (MCI) in susceptible persons. Using Adeona's proprietary, modified oral zinc delivery technologies, Adeona is preparing to initiate the first clinical trial of oral zinc therapy for the once-a-day dietary management of AD and MCI. Adeona is also developing a number of late-stage clinical drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis. For further information, please visit www.adeonapharma.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: CBAI - Cord Blood America, Inc.)

LATEST NEWS!!

Cord Blood America Completes Financings for 2010 Acquisition, Growth Strategy

LAS VEGAS, Jan 11, 2010 -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that it has completed capital raises over the last 18 months totaling $16.8 million, including a new $3 million financing focused on avoiding dilution and being investor-friendly as CBAI puts in place its business strategy for success in 2010.

Specifically, CBAI raised $4M in a short term equity line in July 2008, $2.3M in convertible debt in April 2009, $7.5M in long term equity in June 2009 and entered into agreements for $3M in January 2010 targeted specifically for acquisitions.

In discussing the different financings, CEO and Founder Matthew Schissler said, "Each financing has its own purpose. Organic growth strategies, targeting a specific acquisition, or expanding our revenue base, will determine the proper financing to apply in any one scenario. To the point and as an example, up until today, CBAI did not have any financings at our fingertips which allowed to use cash as payment. They were all share based." "However, that changed today. The latest financing is extremely vital because it allows for cash payments. This type of financing targets acquisitions, specifically ones that have cash flow. It is beneficial for shareholders in that it allows payment for all or at least part of the financing back in cash." Mr. Schissler continued, "Another critical point is that each of the said financings are, in effect, credit lines, which are opportunistic for CBAI. They are tapped by CBAI only if and when we choose to utilize them. This differs greatly from our previous financings which were funded with large sums relatively immediately, creating debt and long term obligations on the balance sheet and overhang in the market. We spent all of 2009 cleaning that up and wish not to repeat that process ever again. With the new financing, we only access the capital at our request." To be noted, in the last 18 months, CBAI has received approximately $2.3M of the $16.8M total, mostly used for the build-out of their new state-of-the art laboratory, leaving $14.5M available for future opportunities.

"We believe all the necessary financial tools are in place to execute our three pillars of success in 2010: organic growth, acquisitions and diversification of revenue streams," said Mr. Schissler.

About Cord Blood America Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: MDCE - Medical Care Technologies Inc.)

LATEST NEWS!!

Medical Care Technologies Inc. Signs Asset Acquisition Agreement

LONDON, Jan 11, 2010 -- Medical Care Technologies Inc. (OTCBB: MDCE) today announced that it has reached a definitive agreement to acquire various technologies from Great Union Corporation, ("GUC") a private Hong Kong corporation.

The Boards of Directors of both companies have unanimously approved the transaction.

Pursuant to the Agreement, and in consideration of 57,300,000 of its common stock, MDCE will acquire GUC's technologies associated with the development and maintenance of secure information systems which increase access to medical resources services, education and wellness, pharmaceutical and nutraceutical products. The transaction is subject to customary closing conditions.

Management believes that the acquisition is a significant step in MDCE's strategy to enter into China's lucrative health care market. With life expectancy of the Chinese population gradually increasing, and as China's population becomes wealthier, patients are demanding better lifestyles and better quality care.

According to the US World Nutraceutical Ingredients Industry, it states that the "World demand for nutrients and minerals is projected to reach $12.6 billion in 2013, it too has predicted that China and India will emerge as the most rapidly expanding nutraceutical ingredient markets as strong economic growth allows them to upgrade and diversify food, beverage and drug production capabilities." It also goes on to state, that "China will remain the largest worldwide producer based on its extensive fine chemicals industry and aggressive pursuit of exports." In China alone nutraceutical sales are estimated to be worth approximately $6 billion in annual sales, according to the China Health Care Association, which is an association attached to China's Ministry of Health. Although the industry is young compared with the U.S., and about one-fourth its size, the potential for sizeable growth is significant due to China's rapid economic growth and increasing consumer demand for natural products that promote health and overall wellness. Patricia Traczykowski, President of MDCE, goes on to state, "I am very excited for our shareholders and for the Company with our most recent acquisition. It is an acquisition which will allow us to target an expanding healthcare segment and will allow us to venture into a country like China which is full of opportunities. Our values will be simple, using technology to provide better health. We plan to offer affordable, standardized and secure software information systems to electronically connect Healthcare Providers, Academic Institutions, Pharmaceutical and Nutraceutical Companies, Alternative Health Industries, and Individual Consumers with healthcare information, products and services in China. Initially, we aim to generate e-management revenues and nutraceutical and pharmaceutical product distribution revenues. Concurrent with and in addition to our main revenue streams, we hope to add to our bottom line through content licensing fees, email marketing revenues and e-commerce." Management intends to immediately begin the process of integrating its technology, services and products into Asia once the registration of the share transfer is completed and it has obtained transfer of the assets, all as contemplated by the Asset Acquisition Agreement.

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (www.medicaretech.com) is traded under the symbol MDCE on the OTCBB and is based in London, England. The Company is in the process of moving its portfolio of oil resources into medical care technologies. The products/services that the company hopes to acquire are intended and will constitute a healthcare delivery and wellness site; dedicated to helping Asian consumers live healthier, more balanced lives. MDCE is planning to provide advanced connectivity, internationally standardized and secure business, technology and information systems to assist the Asian health industry -- physicians, pharmacists, medical institutions, consumers -- access medical resources, health services, education, wellness and pharmaceutical products throughout Asia. MDCE is planning to distribute and provide services at a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Nutraceuticals. Further information on the Company can be found at www.sec.gov and the company's website at www.medicaretech.com

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: AGCZ - Andes Gold Corp.)

LATEST NEWS!!

Andes Gold to Acquire Roman Mine

NEW YORK, NY, Jan 08, 2010 -- Andes Gold Corporation. (PINKSHEETS: AGCZ) announced today that it has opened final discussions to acquire the "Roman Mine," a neighboring property.

The company is pleased to announce that the negotiations for the strategic acquisition of the "Roman Mine" are well underway; discussions started in July of 2009. The property has huge advantages to the company as it has an additional access road, site for an expanded work camp and will add a new access tunnel making three tunnels in total. The company expects to conclude this acquisition on or before February, however several milestones including feasibility study and long range production goals need to be completed as part of the due diligence process.

"The acquisition of the Roman Mine will add two new virgin gold veins of ore production," stated Alex Diaz, President of Andes Gold.

Andes Gold Corporation is a gold producing and exploration company with operations in Ecuador (South America). In the post market meltdown of 2008 the world took shelter in the security of gold pushing the value to over $1,100 USD per ounce by January 2010. Producing gold properties such as Andes Gold will continue to enjoy increased prosperity which can only improve if the price continues to climb.

About Andes Gold Corporation: Andes Gold Corporation is a United States of America registered public company currently operating a gold mining and exploration corporation, through its wholly owned subsidiary company Compania Minera PLS.A. in Ecuador, (South America) which controls a Gold mining and exploration concession called the Miranda Alto. For more information please visit: www.andesgold-ir.com

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: BPAC - BioPack Environmental Solutions, Inc.)

LATEST NEWS!!

Biopack to Showcase New, Innovative Products at Upcoming Exhibitions

HONG KONG, Jan 11, 2010 -- Biopack Environmental Solutions Inc. (OTCBB: BPAC), a designer, manufacturer, and supplier of 100% biodegradable packaging products, is pleased to announce that in its first quarter schedule it intends to introduce its newest products at three major exhibitions in February, 2010.

Biopack intends to showcase its current product line up and roll out the latest in its 'Roots Biopack' line of products featuring its new moisture resistant trays at the following trade shows: Fruit Logistica in Berlin 3-5 February, 2010 More than 2,000 companies from across the entire fresh produce value chain come together in a single location for what is generally considered the leading trade fair for the international fresh produce trade. This specialist trade fair offers those connected with the fresh fruit and vegetable business an ideal opportunity to present their products across the entire added-value chain, from growing to point-of-sale.

Biofach Nuremberg 17-20 February, 2010 Biofach Germany offers an excellent opportunity to network in this major market for organic products. Regular, personal meetings between suppliers and customers are key for business success in Germany. Over 2,700 exhibitors and 1,200 journalists are usually involved with this show Ecopack Birmingham 24-25 February, 2010 Ecopack is the largest packaging event in the United Kingdom. This is a unique annual opportunity to meet suppliers of: Recycling & recyclable materials, Low-waste packaging design, Biodegradable and lightweight materials, Environment-friendly printing, inks & chemicals.

"These three shows represent our first opportunity to introduce our groundbreaking moisture resistant trays on a large scale. These are the first of numerous exhibitions around the world that we plan to participate in during 2010, as we feel there is no replacement for being able to touch, feel and see first-hand the quality of our products." commented Gerald Lau, CEO of Biopack. "Our foremost goal is to position ourselves at the leading edge of the sustainable packaging industry. We intend to drive towards this goal through continuous innovation, research and development, and ingenuity."

*On October 22nd, 2009, Biopack announced the successful initial testing of its proprietary coating application. This coating application was initially tested for moisture resistance; it is especially useful for products that require prolonged moisture resistance such as the mushroom, fresh and frozen meat sectors. The company believes that the future will reveal additional benefits to this coating, allowing Biopack's trays new and innovative uses.

In early testing, Biopack's coated trays can be sealed with a transparent film which is bonded to the coated tray through heat. This process is known as topsealing, an application that was not possible on a commercial scale without Biopack's coating technology. Topsealing allows for a peelable, transparent top, a preferred presentation style for lucrative sectors such as the ready made meal/frozen food packagers. Biopack is currently exploring the possibility of entering into suitable strategic partnerships with lidding film makers to jointly test and commercialize this technology for the sustainable market.

About Biopack: Biopack manufactures 100% biodegradable consumer packaging products from locally available sugar cane waste called Bagasse. Based in Hong Kong with manufacturing facilities in Jiangmen, China, Biopack has earned the "premium brand" label in the biodegradable packaging market in Europe. Distributed under the "Roots Biopack" trademark, Biopack's unique line of compostable packaging is sold in 12 European countries, North America, Hong Kong, Taiwan and South Africa. For investor inquiries and information about our comprehensive line of biodegradable packaging solutions, please visit our website at http://www.biopackenvironmental.com

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: academic, acquisition, alzheimers, amex, art, arthritis, asia, business, california, cancer, ceo, chemicals, children, china, clinical, commercial, consumer, copper, debt, disease, diversification, ecommerce, economic growth, ecuador, education, email, e-mail, england, environment, equity, europe, exploration, fda, film, food, fruit, germany, gold, health, healthcare, hong kong, india, information technology, investment opinion, java, local, london, manufacturer, manufacturing, market, marketing, medical, mining, new york, north america, oil, online, otc, packaging, partnership, pharmaceuticals, physicians, policy, population, pregnancy, president, products, property, rates, research and development, revenue, sales, schedule, software, south africa, south america, sugar, taiwan, technology, trade, trial, unions, united states, vegetable, web, women, zinc